ANGLE plc (AIM: AGL)
Market Cap | 37.09M |
Revenue (ttm) | 2.02M |
Net Income (ttm) | -18.03M |
Shares Out | 322.53M |
EPS (ttm) | -0.07 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 912,206 |
Open | 12.24 |
Previous Close | 12.50 |
Day's Range | 11.20 - 12.95 |
52-Week Range | 7.11 - 37.40 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Dec 27, 2024 |
About ANGLE
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated analysis. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with high analytical sensitivity and specificity for the identification, characterization, and enumera... [Read more]
Financial Performance
In 2023, ANGLE's revenue was 2.19 million, an increase of 109.99% compared to the previous year's 1.04 million. Losses were -20.13 million, -7.17% less than in 2022.
Financial StatementsNews
Angle PLC Announces Research on HER2 Assay Kit Showcased at AACR
RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT INTERNATIONAL LIQUID BIOPSY CONFERENCE Parsortix-based HER2 kit being developed to provide an optimised, easily implemented, ...
Angle PLC Announces Parsortix Based PD-L1 Assay Showcased at AACR
CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment GUILDFORD, UNITED KINGDOM / ACCESSWIRE / November 15, 2024 / ANGL...
ANGLE presents two posters at EACR
PARSORTIX-BASED ASSAYS SHOWCASED AT THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH LIQUID BIOPSIES CONFERENCE Two posters highlight the importance of epitope-independent CTC enrichment and molecular cha...
Angle PLC Announces Parsortix enriched CTC & ctDNA in NSCLC patients
ANGLE plc ("the Company") DNA ANALYSIS OF PARSORTIX-ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIB The addition of CTC-DNA analysis...
Angle PLC Announces Publication Demonstrates CTC Profiling Potential
PUBLICATION DEMONSTRATES POTENTIAL FOR multi-marker CTC profiling IN EARLY PROSTATE CANCER Parsortix enriched CTCs detected at high rates in localised disease Multi-marker profiling of CTCs could supp...
ANGLE PLC (ANPCY) (Q2 2024) Earnings Call Transcript Highlights: Key Takeaways from the ...
ANGLE PLC (ANPCY) (Q2 2024) Earnings Call Transcript Highlights: Key Takeaways from the Half-Year Report
Half Year 2024 Angle PLC Earnings Call Transcript
Half Year 2024 Angle PLC Earnings Call Transcript
Angle Plc reports 1H results
Angle Plc (ANPCY) reports 1H revenue of £1M, with a reduced loss of 21% at £7.7 million.
Angle PLC Announces 100th Publication Supporting Parsortix System Use
GUILDFORD, SURREY / ACCESSWIRE / September 26, 2024 / Whole Genomic Sequencing and machine learning identifies key cancer genes associated with DNA proliferation and repair ANGLE plc (AIM:AGL)(OTCQX:A...
Angle PLC Announces Half-year Report
Interim Results for the six months ended 30 June 2024 LARGE PHARMA STRATEGY IMPLEMENTED SUCCESSFULLY Three Large Pharma contracts secured each with substantial revenue potential Strategic decision pos...
Angle PLC Announces Exclusive agreement for DNA NGS panel
ANGLE ANNOUNCES NEXT GENERATION SEQUENCING ASSAY AGREEMENT WITH NUPROBE Option for exclusive licence to highly sensitive NGS assay for use with CTCs and dual analysis of CTCs with ctDNA Combining the ...
Angle PLC Announces Agreement with Recursion Pharmaceuticals
New pharma agreement for Parsortix CTC analysis GUILDFORD, SURREY / ACCESSWIRE / September 19, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulatin...
Angle PLC Announces Notice of Interim Results and Webcast
Notice of Interim Results and Webcast GUILDFORD, SURREY / ACCESSWIRE / September 17, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour c...
What's Going On With Plug Power Stock Today?
Plug Power, Inc. (NASDAQ: PLUG) shares are trading lower on Thursday. According to Benzinga Pro , PLUG stock has lost over 74% in the past year. Investors can gain exposure to the stock via Global X ...
Angle PLC - Data Supporting FDA Approval Published in Journal
DATA SUPPORTING FDA APPROVAL PUBLISHED IN HIGH-IMPACT JOURNAL Publication of results from ANGLE's Parsortix PC1 system validates use of Parsortix System for CTC isolation and harvest in metastatic bre...
Angle PLC Announces Standard Form for Notification of Major Holdings
GUILDFORD, SURREY / ACCESSWIRE / July 18, 2024 / TR-1: TR-1:Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microso...
Angle PLC Announces Result of 2024 Annual General Meeting
GUILDFORD, SURREY / ACCESSWIRE / July 11, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today...
Angle PLC Announces Posting of 2023 Annual Report & Notice of the AGM
GUILDFORD, SURREY / ACCESSWIRE / June 18, 2024 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use...
Angle PLC Announces Parsortix and Assays being Showcased at EACR 2024
PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT THE 2024 ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH ANGLE presenting two posters highlighting the utility of CTC & ctDNA dual analys...
Angle PLC Announces Preliminary Results
Preliminary Results for the year ended 31 December 2023 COMMERCIALISATION BUILDING, WITH REVENUE MORE THAN DOUBLED New products and services launched; and breakthrough studies completed on combined ct...
Angle PLC Announces Study of Ovarian Cancer CTCs Using Parsortix
INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALS The study investigated 123 metastatic ovarian cance...
Angle PLC Announces New Commercial Agreement with Large Pharma
ANGLE commissioned to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies GUILDFORD, SURREY / ACCESSWIRE / May 3, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a ...
Angle PLC Announces New Commercial Agreement with AstraZeneca
ANGLE signs agreement to tailor existing Parsortix-based DNA damage response assay for use in pharmaceutical R&D GUILDFORD, SURREY / ACCESSWIRE / April 24, 2024 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a wo...
Angle PLC Announces US and EU Patents for Innovative CellKeep(TM) Slide
Proprietary cell recovery device and method eliminates over 70% of CTC cell loss from standard microscopy techniques increasing assay sensitivity GUILDFORD, SURREY / ACCESSWIRE / April 22, 2024 / ANGL...
Angle PLC Announces Parsortix HER2 Assay Showcased at AACR 2024
PARSORTIX HER2 ASSAY SHOWCASED AT PRESTIGIOUS INTERNATIONAL CANCER CONFERENCE CTC HER2 assay being developed for HER2 targeted drugs and antibody drug conjugates presented at internationally renowned ...